about
Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndromeValproate in the treatment of epilepsy in girls and women of childbearing potentialPharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramineConcise Review: Exciting Cells: Modeling Genetic Epilepsies with Patient-Derived Induced Pluripotent Stem CellsDrosophila sodium channel mutations: Contributions to seizure-susceptibilityThe safety and tolerability of newer antiepileptic drugs in children and adolescents.Knock-in model of Dravet syndrome reveals a constitutive and conditional reduction in sodium current.Screening of conventional anticonvulsants in a genetic mouse model of epilepsy.Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome).The hidden genetics of epilepsy-a clinically important new paradigm.Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome(1,2,3).Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome.Genetic forms of epilepsies and other paroxysmal disordersGenetic variations and associated pathophysiology in the management of epilepsy.Temperature-dependent changes in neuronal dynamics in a patient with an SCN1A mutation and hyperthermia induced seizuresHuperzine A Provides Robust and Sustained Protection against Induced Seizures in Scn1a Mutant Mice.Audit of use of stiripentol in adults with Dravet syndromeThe core Dravet syndrome phenotype.Pharmacogenomics and epilepsy: the road ahead.The ketogenic diet in Dravet syndrome.Stiripentol in Dravet syndrome: results of a retrospective U.S. study.Therapeutic approach to epileptic encephalopathies.Clinical management of epileptic encephalopathies of childhood and infancy.Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy.The genetics of the epilepsies.Vagus Nerve Stimulation in Intractable Epilepsy Associated With SCN1A Gene Abnormalities.Of fish and men.Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.Epilepsy treatment: a paradigm shift is urgently need.Dravet syndrome: a new causative SCN1A mutation?Cognitive and social impairment in mouse models mirrors dravet syndrome.Genetics of Epilepsy in Clinical Practice.Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome.Stiripentol for dravet syndrome: is it worth it?Reduced dendritic arborization and hyperexcitability of pyramidal neurons in a Scn1b-based model of Dravet syndrome.Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies.Drug development: Illuminated targets.SCN1A testing for epilepsy: application in clinical practice.Successful use of fenfluramine as an add-on treatment for Dravet syndrome.Epilepsy syndromes during the first year of life and the usefulness of an epilepsy gene panel.
P2860
Q26776222-582C7D0E-43A0-4F58-9E41-7BB344A09CCBQ26865670-014ECA96-A2EB-4598-9E8F-5D7E64E0A17FQ27308068-1E12930B-AEE7-4D64-BEEB-5F5CB0521DCEQ28081651-B5C37E5C-13AF-499D-8AEC-AE0D9787FEC6Q28082964-1B6CAB48-1146-491B-A92C-75FA07C58990Q30454834-EB768100-FB0B-4214-B22D-D3C10C137916Q30585940-D7A8298C-64A6-4F9E-9DA8-61D2788EBE64Q33646252-87C09B16-4107-4C01-9266-DAA0562291CBQ34302354-B1FEB9DF-DC17-47C4-85D0-6632761295A9Q34415194-64763B94-28FA-42B9-B8D3-3A8933C3B2C6Q35805872-364D3FD4-A5A0-4A8C-9BCA-27EED644C124Q36776559-8C539903-5539-48B3-9095-242538FB5A77Q36805699-19204B81-28EA-44F9-87A8-8ACC5A278045Q36925220-5092AE22-3C1D-4505-994A-ED585545A4CDQ37223382-97CE1904-F47C-46DE-9145-87B14A12E6F9Q37342533-144C5359-1346-4116-81C9-5C31C491AE0BQ37505426-F82C2ECE-B750-44F2-A3B5-4CA1421CABF2Q37861252-5A012421-2C1B-4384-9F75-14677563DB0EQ37946957-83F37B5F-0603-48B3-AC54-2D6C6FDF27D7Q38105061-FCB905D0-997A-48C3-AD90-A34DD2CF0139Q38121171-C1C56A45-4EE0-4226-9339-51CD18F46701Q38191250-35E15B62-DD44-44F0-863F-83316FDDB558Q38213837-F62215B6-5C8F-4CDD-BDB5-F46AC19DD471Q38371961-40E63C37-9A92-4689-93BC-63C462ADD736Q38501842-8D8D78BD-BFA0-4E57-97A4-03F86840D45BQ39082444-A65B9912-9AEB-4AC2-9769-86EC7E838CFBQ39256507-E6FC1860-5C94-4412-80A8-4DBD149A0B3BQ39416423-9AE0AB45-C017-4410-AFF9-03176A560260Q39438811-C06553ED-A824-46AF-83DF-214454C87EACQ40058540-6601BC30-078B-4B90-BDF3-563B6EBBCDDCQ40226059-5968E17B-82BD-4A4E-BEF1-CE52B5DC67FDQ40597290-C29B7686-1702-41DA-8F48-6508537A1750Q41379608-E9AAF2ED-13F2-4DC0-874B-881E13D865E6Q41813248-43108884-BD16-4DF8-9227-763B0B98F4CDQ42655726-4EC0E2EE-469B-441C-A7A5-B78DA2AA623EQ47269323-7CBB375B-6978-41FE-AE24-92C688502D40Q48070946-627F565E-41DA-4726-BA50-731C5CE110B5Q50748696-982ED940-CDAE-4AE8-95E1-2954E020F526Q51342135-9838476A-2F5C-48CC-9197-BB51533709D3Q55294333-80BF33BC-D09C-4A37-A3AA-1D3993362F50
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The pharmacologic treatment of Dravet syndrome
@ast
The pharmacologic treatment of Dravet syndrome
@en
type
label
The pharmacologic treatment of Dravet syndrome
@ast
The pharmacologic treatment of Dravet syndrome
@en
prefLabel
The pharmacologic treatment of Dravet syndrome
@ast
The pharmacologic treatment of Dravet syndrome
@en
P2860
P3181
P1433
P1476
The pharmacologic treatment of Dravet syndrome
@en
P2093
Olivier Dulac
P2860
P3181
P356
10.1111/J.1528-1167.2011.03007.X
P478
52 Suppl 2
P577
2011-04-01T00:00:00Z